Gandhi Damaj

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos et al. · The Lancet Oncology · 2020 · 587 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Michael Wang, Simon Rule, Pier Luigi Zinzani et al. · The Lancet · 2017 · 448 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Steven Le Gouill, Catherine Thiéblemont, Lucie Obéric et al. · New England Journal of Medicine · 2017 · 412 citations · Full text

Life Sciences, Immunology, Oncology +16

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

Delphine Rossille, M Gréssier, Diane Damotte et al. · Leukemia · 2014 · 324 citations

Medicine, Hematology, Oncology +14

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

David Ghez, Anne Calleja, Caroline Protin et al. · Blood · 2018 · 296 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14